HCPCS code J9293: Mitoxantrone injection, per 5 mg2026 Medicare rate & RVUs in Maryland
J9293 reports mitoxantrone hydrochloride for injection in 5-mg units when the drug is furnished for Medicare-covered treatment.
CMS doesn’t publish an office rate for J9293 in Maryland.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J9293 covers
Mitoxantrone hydrochloride is an injectable antineoplastic drug used in oncology treatment, including selected leukemias and advanced prostate cancer; it has also been used for selected patients with worsening multiple sclerosis. It is administered intravenously in settings such as oncology practices and hospital outpatient infusion departments. J9293 identifies the drug, not its administration; a separately reportable administration service is coded separately.
CMS assigns J9293 status E, excluding it from the physician fee schedule. When Medicare covers the drug, it is a Part B drug generally paid using CMS's quarterly ASP drug pricing files; special Medicare coverage instructions apply. Each unit represents 5 mg of mitoxantrone hydrochloride, so a 30-mg dose is 6 units. Documentation should support the drug supplied and the dose administered.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J9293 pays more and less in Maryland
The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.
| Payment locality | Office | Facility |
|---|---|---|
| Baltimore area, MD | Unavailable | Unavailable |
| Rest of Maryland | Unavailable | Unavailable |
| Washington, DC area | Unavailable | Unavailable |
How the J9293 rate is calculated
Each of J9293’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J9293
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J9293
J9293 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J9293
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J9293 isn’t priced in this setting.
J9293 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- J9280Mitomycin injectionPer 5 mg
- J9280 identifies mitomycin for injection. J9293 identifies mitoxantrone hydrochloride, a different drug.
- J9281Mitomycin instillationPer 1 mg
- J9281 identifies mitomycin administered by instillation; J9293 is for mitoxantrone hydrochloride supplied for injection.
- J9282Mitomycin instillationIntravesical, per 1 mg
- J9282 identifies mitomycin for intravesical instillation. J9293 is for mitoxantrone hydrochloride, not bladder instillation.
J9293 billing questions
How many J9293 units represent a 30-mg dose?
Each unit represents 5 mg, so a 30-mg dose corresponds to 6 units.
Does J9293 include the infusion administration?
No. J9293 identifies the drug; a separately reportable chemotherapy administration service is coded separately.
How is J9293 different from the mitomycin codes?
J9293 identifies mitoxantrone hydrochloride. J9280, J9281, and J9282 identify mitomycin in injection or instillation forms.
What documentation supports J9293 units?
Document the mitoxantrone supplied and the dose administered so the reported 5-mg units can be checked against the drug record.
Does status E mean Medicare never pays for J9293?
No. Status E excludes the code from the physician fee schedule. When Medicare covers the drug, it is a Part B drug generally paid using quarterly ASP drug pricing files.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J9293 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist